AR067786A1 - Inhibicion relacionada con arni (arn de interferencia) de senales tnfalfa (factor de necrosis tumoral) para el tratamiento de glaucoma - Google Patents

Inhibicion relacionada con arni (arn de interferencia) de senales tnfalfa (factor de necrosis tumoral) para el tratamiento de glaucoma

Info

Publication number
AR067786A1
AR067786A1 ARP080103368A ARP080103368A AR067786A1 AR 067786 A1 AR067786 A1 AR 067786A1 AR P080103368 A ARP080103368 A AR P080103368A AR P080103368 A ARP080103368 A AR P080103368A AR 067786 A1 AR067786 A1 AR 067786A1
Authority
AR
Argentina
Prior art keywords
tnfalfa
necrosis factor
tumor necrosis
glaucoma
interference rna
Prior art date
Application number
ARP080103368A
Other languages
English (en)
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Publication of AR067786A1 publication Critical patent/AR067786A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se provee ARN de interferencia para la inhibicion de factor de necrosis tumoral alfa (TNFalfa) al silenciar la expresion de mARN del receptor 1 de receptor de superficie celular TNFalfa (TNFR1), o al silenciar la expresion de mARN de la enzima convertidora de TNFalfa (TACE/ADAM17). El silenciamiento de dichos objetivos de TNFalfa, en particular, es util para tratar pacientes que tienen una condicion relacionada con TNFalfa o están en situacion de riesgo de desarrollar una condicion relacionada con TNFalfa, tales como las condiciones oculares asociadas con una elevada presion ocular (IOP), incluso glaucoma e hipertension ocular.
ARP080103368A 2007-08-03 2008-08-01 Inhibicion relacionada con arni (arn de interferencia) de senales tnfalfa (factor de necrosis tumoral) para el tratamiento de glaucoma AR067786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95380907P 2007-08-03 2007-08-03

Publications (1)

Publication Number Publication Date
AR067786A1 true AR067786A1 (es) 2009-10-21

Family

ID=40338355

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103368A AR067786A1 (es) 2007-08-03 2008-08-01 Inhibicion relacionada con arni (arn de interferencia) de senales tnfalfa (factor de necrosis tumoral) para el tratamiento de glaucoma

Country Status (5)

Country Link
US (3) US20090035225A1 (es)
AR (1) AR067786A1 (es)
CL (1) CL2008002278A1 (es)
TW (1) TW200914052A (es)
WO (1) WO2009020848A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168786A1 (en) * 2014-05-05 2015-11-12 Val-Chum, Limited Partnership Method for decreasing retinal ganglion cells degeneration
WO2016103042A1 (en) * 2014-12-25 2016-06-30 Guangzhou Ribobio Co., Ltd. Compositions and methods for inhibiting expression of adamts-5 and adam17
CN104498498A (zh) * 2014-12-25 2015-04-08 广州市锐博生物科技有限公司 抑制ADAM17基因的siRNA及其应用
GB201510758D0 (en) * 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3638705B1 (en) 2017-06-13 2024-02-28 Alcon Inc. Intraocular lens compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531128B1 (en) * 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
JP2003529561A (ja) * 2000-02-08 2003-10-07 ワックス、マーティン、ビー 緑内障の治療法
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
EP1560931B1 (en) * 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
EP2018426B1 (en) * 2006-05-19 2013-05-15 Alcon Research, Ltd. Rnai-mediated inhibition of tumor necrosis factor alpha-related conditions

Also Published As

Publication number Publication date
US20090035225A1 (en) 2009-02-05
TW200914052A (en) 2009-04-01
CL2008002278A1 (es) 2009-07-17
WO2009020848A2 (en) 2009-02-12
WO2009020848A8 (en) 2009-07-23
US20110135579A1 (en) 2011-06-09
US20150057336A1 (en) 2015-02-26
US8865670B2 (en) 2014-10-21
WO2009020848A3 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
AR067786A1 (es) Inhibicion relacionada con arni (arn de interferencia) de senales tnfalfa (factor de necrosis tumoral) para el tratamiento de glaucoma
UY30361A1 (es) Inhibición mediada por el arni de las afecciones vinculadas al factor a (alfa) de necrosis tumoral
NI201900062A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
AR056852A1 (es) INHIBICIoN DE HIF1A INTERMEDIADO POR RNAI PARA EL TRATAMIENTO DE ANGIOGENESIS OCULAR
DOP2020000241A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
UY30060A1 (es) Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos
CL2020000483A1 (es) Nuevos usos de derivados de piperidinil–indol.
UY32030A (es) "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AR071146A1 (es) Inhibicion relacionada con arni de la via de senales tnf alfa para el tratamiento de angiogenesis ocular, uso de una molecula de arn de interferencia y molecula de arn de interferencia
GT201200318A (es) Anticuerpos hacia gdf8 humano
EA201070035A1 (ru) Модулирующие сиртуин соединения
UY33625A (es) Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos
MX2020003557A (es) Terapias genicas para los trastornos lisosomales.
CO6390041A2 (es) Agentes y antagonistas fijaodres de notch y metodos para el uso de los mismos.
DE602007008237D1 (de) Benzamidderivate und assoziierte verwendungen
BRPI0710085B8 (pt) composições oftálmicas e seus kits
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
UY28709A1 (es) Derivados de prostaglandinas
UY33481A (es) Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
UY29348A1 (es) Inhibición de objetivos oculares mediada por arni
SV2009002859A (es) Combinacion de oxazolidinonas sustituidas para la profilaxis y el tratamiento de alteraciones del flujo sanguineo cerebral
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112015028613A2 (pt) análogos de uréia com ligações por pontes substituída como moduladores de sirtuína

Legal Events

Date Code Title Description
FB Suspension of granting procedure